Active, not recruitingPHASE2, PHASE3NCT04442022
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Studying B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Karyopharm Therapeutics Inc
- Intervention
- Selinexor (combination therapy)(drug)
- Enrollment
- 501 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (30)
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States
- Arizona Oncology Associates, Tucson, Arizona, United States
- The Oncology Institute (TOI) Clinical Research, Cerritos, California, United States
- Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States
- Norton Cancer Institute, St. Matthews, Louisville, Kentucky, United States
- Tulane Cancer Center, New Orleans, Louisiana, United States
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
- Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States
- New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
- Stony Brook, Stony Brook, New York, United States
- Gabrail Cancer Center Research LLC, Canton, Ohio, United States
- Texas Oncology - Medical City Dallas, Dallas, Texas, United States
- Texas Oncology - Presbyterian Dallas Cancer Center, Dallas, Texas, United States
- Texas Oncology - Sammons, Dallas, Texas, United States
- Texas Oncology - Fort Worth, Fort Worth, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04442022 on ClinicalTrials.govOther trials for B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaCity of Hope Medical Center
- RECRUITINGPHASE1NCT07361224Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.Tel-Aviv Sourasky Medical Center
- RECRUITINGPHASE2NCT07523737Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaBeijing Tongren Hospital
- RECRUITINGPHASE1, PHASE2NCT07283679Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07135466A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell MalignanciesSheba Medical Center
- ACTIVE NOT RECRUITINGNCT07480837Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07480850Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT07376642A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaSuzhou Immunofoco Biotechnology Co., Ltd